TY - JOUR
T1 - Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT) :
T2 - an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)
AU - Saccardi, Riccardo
AU - Putter, Hein
AU - Eikema, Dirk-Jan
AU - Busto, María Paula
AU - McGrath, Eoin
AU - Middelkoop, Bas
AU - Adams, Gillian
AU - Atlija, Marina
AU - Ayuk, Francis
AU - Baldomero, Helen
AU - Beguin, Yves
AU - de la Camara, Rafael
AU - Cedillo Cedillo, Angel
AU - Balari, Anna María Sureda
AU - Chabannon, Christian
AU - Corbacioglu, Selim
AU - Dolstra, Harry
AU - Duarte, Rafael
AU - Duléry, Rémy
AU - Greco, Raffaella
AU - Gusi, Andreu
AU - Hamad, Nada
AU - Kenyon, Michelle
AU - Kroeger, Nicolaus
AU - Labopin, Myriam
AU - Lee, Julia
AU - Ljungman, Per
AU - Manson, Lynn
AU - Mensil, Florence
AU - Milpied, Noel
AU - Mohty, Mohamad
AU - Oldani, Elena
AU - Orchard, Kim
AU - Passweg, Jakob
AU - Pearce, Rachel
AU - de Latour, Régis Peffault
AU - Poirel, Hélène A.
AU - Rintala, Tuula
AU - Rizzo, J. Douglas
AU - Ruggeri, Annalisa
AU - Sanchez-Martinez, Carla
AU - Sanchez-Guijo, Fermin
AU - Sánchez-Ortega, Isabel
AU - Trnková, Marie
AU - Valcárcel, David
AU - Wilcox, Leonie
AU - de Wreede, Liesbeth C.
AU - Snowden, John A.
PY - 2023
Y1 - 2023
N2 - From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide individual EBMT Centers with a means of quality-assuring the HSCT process and meeting FACT-JACIE accreditation requirements relating to 1-year survival outcomes. Informed by previous experience from Europe, North America and Australasia, the Clinical Outcomes Group (COG) established criteria for patient and Center selection, and a set of key clinical variables within a dedicated statistical model adapted to the capabilities of the EBMT Registry. The first phase of the project was launched in 2019 to test the acceptability of the benchmarking model through assessment of Centers' performance for 1-year data completeness and survival outcomes of autologous and allogeneic HSCT covering 2013-2016. A second phase was delivered in July 2021 covering 2015-2019 and including survival outcomes. Reports of individual Center performance were shared directly with local principal investigators and their responses were assimilated. The experience thus far has supported the feasibility, acceptability and reliability of the system as well as identifying its limitations. We provide a summary of experience and learning so far in this 'work in progress', as well as highlighting future challenges of delivering a modern, robust, data-complete, risk-adapted benchmarking program across new EBMT Registry systems.
AB - From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide individual EBMT Centers with a means of quality-assuring the HSCT process and meeting FACT-JACIE accreditation requirements relating to 1-year survival outcomes. Informed by previous experience from Europe, North America and Australasia, the Clinical Outcomes Group (COG) established criteria for patient and Center selection, and a set of key clinical variables within a dedicated statistical model adapted to the capabilities of the EBMT Registry. The first phase of the project was launched in 2019 to test the acceptability of the benchmarking model through assessment of Centers' performance for 1-year data completeness and survival outcomes of autologous and allogeneic HSCT covering 2013-2016. A second phase was delivered in July 2021 covering 2015-2019 and including survival outcomes. Reports of individual Center performance were shared directly with local principal investigators and their responses were assimilated. The experience thus far has supported the feasibility, acceptability and reliability of the system as well as identifying its limitations. We provide a summary of experience and learning so far in this 'work in progress', as well as highlighting future challenges of delivering a modern, robust, data-complete, risk-adapted benchmarking program across new EBMT Registry systems.
KW - Haematological cancer
KW - Therapeutics
UR - https://www.scopus.com/pages/publications/85149466633
U2 - 10.1038/s41409-023-01924-6
DO - 10.1038/s41409-023-01924-6
M3 - Article
C2 - 36894635
SN - 0268-3369
SP - 1
EP - 8
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
ER -
